Stoke TherapeuticsSTOK +5.09%45 Beneish M-Score is 50.63 as of Jun. 27, 2026, which is 5653% above its 10-year median of 0.88. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Stoke Therapeutics ranks worse than 97.83% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 50.63 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Stoke Therapeutics's Beneish M-Score or its related term are showing as below:
STOK'
s Beneish M-Score Range Over the Past 10 Years
Min: -4.53 Med: 0.88 Max: 78.24
Current: 50.63
During the past 9 years, the highest Beneish M-Score of Stoke Therapeutics was 78.24. The lowest was -4.53. And the median was 0.88.
Stoke Therapeutics Beneish M-Score Related Terms
Stoke Therapeutics Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs SION, RXRX, VRDN: Beneish M-Score Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Stoke Therapeutics for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 60.3113
+
0.528 * 1
+
0.404 * 2.7374
+
0.892 * 0.168
+
0.115 * 0.965
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 8.0958
+
4.679 * -0.05162
-
0.327 * 0.8382
=
50.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(2.091 / (2.091 + 7.442))
/
(1.732 / (1.732 + 5.888))
=
0.219343
/
0.227297
=
0.965
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-169.767 - -0.061
-
-146.824)
/
443.277
=
-0.05162
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Stoke Therapeutics has a M-score of 50.63 signals that the company is likely to be a manipulator.
Stoke Therapeutics (STOK) has a Beneish M-Score of 50.63 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stoke Therapeutics and its competitors. This is 5653% above median its historical median of 0.88. According to the industry distribution chart, Stoke Therapeutics ranks #813 out of 831 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Stoke Therapeutics' Beneish M-Score too high?
Stoke Therapeutics' current Beneish M-Score of 50.63 is 5653% above median its 10-year median of 0.88. Based on the distribution chart, Stoke Therapeutics ranks #813 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Beneish M-Score compare to SION and RXRX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #813 out of 831 companies for Beneish M-Score. This places Stoke Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Beneish M-Score is 50.63, which is 5653% above median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current Beneish M-Score is 50.63, which is 5653% above median its 10-year median of 0.88. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Beneish M-Score is 50.63 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Beneish M-Score: 50.63 (5653% above median its 10-year median of 0.88)
GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
